-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2025-522070-36-00
5
2025-12-15
immune thrombocytopenia (ITP)
-
2025-520982-39-00
5
2025-12-09
Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
-
2025-521040-37-00
5
2025-11-26
HER2-positive early breast cancer
-
2023-507192-22-00
7
2025-10-24
Methyl CpG binding protein 2 (MECP2) Duplication Syndrome (MDS)
-
2024-518296-56-00
5
2025-09-29
Crohn’s Disease
-
2023-508057-19-00
5
2025-09-23
Advanced HER2-expressing Biliary Tract Cancer
-
2024-520107-12-00
5
2025-09-03
Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
-
2024-517589-41-00
1
2025-08-04
Advanced solid tumors
-
2024-518502-40-00
9
2025-07-28
Immune Thrombocytopenia
-
2024-512360-55-00
4
2025-06-30
Unresectable locally recurrent or metastatic hormone receptor (HR)-pos
-
2024-512011-45-00
7
2025-06-17
Unresectable locally advanced or metastatic colorectal cancer
-
2024-513965-38-01
5
2025-06-16
Sjögren's Disease
-
2024-511458-32-00
5
2025-06-15
Ulcerative colitis
-
2024-517819-74-00
9
2025-06-02
Pancreatic Ductal Adenocarcinoma
-
2024-515459-39-00
7
2025-05-08
Advanced or Metastatic Squamous Solid Tumors
-
2023-505172-29-00
4
2025-04-24
Resectable Non-small Cell Lung Cancer
-
2024-515451-38-00
5
2025-02-27
Primary Immune thrombocytopenia (ITP)
-
2024-513317-12-00
5
2025-02-05
Pancreatic cancer
-
2024-519132-17-00
4
2025-01-29
NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA
-
2024-513077-48-00
5
2024-12-19
O6-methylguanine methyltransferase (MGMT) unmethylated glioblastoma
-
2024-512926-27-00
5
2024-12-12
patients with estrogen receptor-positive/human epidermal growth factor
-
2023-509482-20-00
4
2024-12-03
Solid Tumors
-
2024-519113-59-00
4
2024-11-20
Hepatocellular carcinoma